{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B-cell+Lymphomas+%28Phase+1%29&page=8", "query": { "condition": "B-cell Lymphomas (Phase 1)", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 1136, "total_pages": 114, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B-cell+Lymphomas+%28Phase+1%29&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B-cell+Lymphomas+%28Phase+1%29&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-05T20:11:26.893Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01865617", "title": "Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "CD19-Positive Neoplastic Cells Present", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Small Lymphocytic Lymphoma", "Refractory Acute Lymphoblastic Leukemia", "Refractory Chronic Lymphocytic Leukemia", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Mantle Cell Lymphoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 204, "start_date": "2013-05-22", "completion_date": "2021-03-26", "has_results": true, "last_update_posted_date": "2022-05-25", "last_synced_at": "2026-10-05T20:11:26.893Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01865617" }, { "nct_id": "NCT00003874", "title": "Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma" ], "interventions": [ { "name": "monoclonal antibody CD19", "type": "BIOLOGICAL" }, { "name": "monoclonal antibody CD20", "type": "BIOLOGICAL" }, { "name": "in vitro-treated peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "70 Years", "sex": "ALL", "summary": "Up to 70 Years" }, "enrollment_count": null, "start_date": "1999-02", "completion_date": "2001-09", "has_results": false, "last_update_posted_date": "2011-11-29", "last_synced_at": "2026-10-05T20:11:26.893Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003874" }, { "nct_id": "NCT00323323", "title": "CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "CHOP", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Plasma Samples", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2004-03", "completion_date": "2016-10", "has_results": false, "last_update_posted_date": "2017-01-20", "last_synced_at": "2026-10-05T20:11:26.893Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00323323" }, { "nct_id": "NCT04884035", "title": "Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, B-Cell" ], "interventions": [ { "name": "CC-220", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "CC-99282", "type": "DRUG" }, { "name": "Polatuzumab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 224, "start_date": "2021-09-15", "completion_date": "2028-12-01", "has_results": false, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-10-05T20:11:26.893Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Marietta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04884035" }, { "nct_id": "NCT01397825", "title": "MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diffuse Large B-Cell Lymphoma", "Transformed Follicular Lymphoma", "Mantle Cell Lymphoma", "Burkitt's Lymphoma" ], "interventions": [ { "name": "Alisertib (MLN8237)", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2011-08-09", "completion_date": "2016-10-05", "has_results": true, "last_update_posted_date": "2018-03-27", "last_synced_at": "2026-10-05T20:11:26.893Z", "location_count": 15, "location_summary": "Tucson, Arizona • Beverly Hills, California • Burbank, California + 12 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Burbank", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT01397825" }, { "nct_id": "NCT04933617", "title": "Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Burkitt Lymphoma", "High-grade B-cell Lymphoma", "T-cell/Histocyte-rich Large B-cell Lymphoma", "Diffuse Large B-Cell Lymphoma (DLBCL)", "Germinal Center B-cell Type (GCB)" ], "interventions": [ { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Copanlisib", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "ECHO", "type": "DIAGNOSTIC_TEST" }, { "name": "EKG", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI Brain", "type": "DIAGNOSTIC_TEST" }, { "name": "18F-FDG - PET", "type": "DIAGNOSTIC_TEST" }, { "name": "CT Scan", "type": "DIAGNOSTIC_TEST" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Lumbar Puncture (LP)", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "DIAGNOSTIC_TEST", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2022-03-24", "completion_date": "2023-11-30", "has_results": true, "last_update_posted_date": "2024-07-09", "last_synced_at": "2026-10-05T20:11:26.893Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04933617" }, { "nct_id": "NCT00784927", "title": "Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "lenalidomide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 36, "start_date": "2008-11", "completion_date": "2016-02", "has_results": true, "last_update_posted_date": "2016-10-07", "last_synced_at": "2026-10-05T20:11:26.893Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00784927" }, { "nct_id": "NCT01995669", "title": "Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Grade 3a Follicular Lymphoma", "Recurrent Follicular Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Small Lymphocytic Lymphoma", "Refractory Follicular Lymphoma", "Refractory Marginal Zone Lymphoma", "Refractory Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2014-05-27", "completion_date": "2023-01-23", "has_results": true, "last_update_posted_date": "2025-06-24", "last_synced_at": "2026-10-05T20:11:26.893Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01995669" }, { "nct_id": "NCT00073931", "title": "Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "autologous bone marrow transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "tositumomab and iodine I 131 tositumomab", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "60 Years to 80 Years" }, "enrollment_count": 25, "start_date": "1999-10", "completion_date": "2014-07", "has_results": false, "last_update_posted_date": "2015-02-05", "last_synced_at": "2026-10-05T20:11:26.893Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00073931" }, { "nct_id": "NCT00003956", "title": "Combination Chemotherapy in Treating Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "fluorouracil", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "lonafarnib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "1999-04", "completion_date": "2009-12", "has_results": false, "last_update_posted_date": "2013-04-04", "last_synced_at": "2026-10-05T20:11:26.893Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003956" } ] }